Global Drug Forecast and Market Analysis for Angina Pectoris to 2028 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Angina Pectoris: Global Drug Forecast and Market Analysis to 2028" report has been added to ResearchAndMarkets.com's offering.

This report focuses on the following forms of angina: stable angina (atherosclerotic obstruction), microvascular, and variant. New therapies entering the market will be the main drivers of growth, with one gene-based therapy, Generx (Ad5FGF-4), and two cell-therapy treatments, CLBS16 and CLBS14 expected to launch in the US during the forecast period. Other major drivers for the angina market are the aging global population, enhanced survival after an MI, and the increasing prevalence of obesity, diabetes, and hypertension. Based on epidemiological analysis, the number of diagnosed prevalent cases of stable angina will grow by 16.09% over the forecast period at an AGR of 1.60% from 11,853,368 cases in 2018 to 13,761,123 cases by 2028 in the seven major pharmaceutical markets (7MM) covered in this report, the US, 5EU and Japan. Diagnosed prevalent cases of microvascular angina will grow by 16.25% from 3,886,426 cases in 2018 to 4,518,109, while variant angina will grow by 16.23% from 49,258 cases in 2018 to 57,255 cases by 2028.

The report projects the antianginal drug marketplace for stable, microvascular and variant angina within the 7MM will grow from $2.5B in 2018 at a modest compound annual growth rate (CAGR) of 2.6% to $3.2B by 2028. In particular, the report expects the US market will contribute the most to the antianginal market's growth, contributing $1.8B sales in 2018 (72% of the global antianginal market) and $2.5B in 2028 (78% of the global antianginal market).

Key Highlights

• The proportion of people at risk of developing angina is expected to increase over the 10-year forecast period due to the growing aging population, increased survival after myocardial infarction (MI), and the rise in the prevalence of obesity and diabetes.
• The potential launch of four late-stage pipeline agents will increase the number of patients who can be offered pharmacological treatment options. In addition, three of these drugs in late-stage development are expected to have a high annual cost of therapy (ACOT), a factor that will contribute to notable profitability.
• Microvascular angina is being increasingly recognized in clinical practice and there has been a renewed interest among the medical community to understand the pathophysiological mechanisms underpinning its pathogenesis.
• Despite the plethora of therapies currently available to angina patients, there is still room for improvement within the treatment space. The most recognizable is the need for novel treatment options for refractory patients.

Key Questions Answered

• Which unmet needs are the most pressing in the 7MM?
• Where should pharmaceutical companies focus drug development efforts in order to become a significant player in the space?
• What are the most promising late-stage candidates and how much they expected to generate over the forecast period?
• What do KOLs say about their clinical and commercial positioning?
• Which have been historically the companies leading the way?
• What new companies are emerging in the space?

Scope

• Overview of chronic forms of angina pectoris (stable, microvascular, variant) including epidemiology, disease etiology and management.
• Topline angina pectoris drugs market revenue (including antianginals and drugs used for secondary prevention of CV events), annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
• Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5U and Japan over the 10-year forecast period.
• Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
• Analysis of the current and future market competition in the global angina pectoris therapeutics market. Insightful review of the key industry drivers, restraints and challenges.

Key Topics Covered:

1 Table of Contents

2 Executive Summary

2.1 Moderate Growth in the Angina Market Is Expected to Be Driven by US Sales

2.2 Small Biotech Companies Pursuing Therapeutic Angiogenesis

2.3 Various Unmet Needs Remain in Refractory, Microvascular, and Variant Angina

2.4 Gene and Cell-Based Therapies Will Face Difficulties Penetrating the Market

2.5 What Do Physicians Think?

3 Introduction

4 Disease Overview

4.1 Etiology and Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.5 Epidemiological Forecast for Angina Pectoris, 2018-2028

5.6 Discussion

6 Disease Management

7 Competitive Assessment

8 Unmet Needs and Opportunity Assessment

9 Pipeline Assessment

10 Current and Future Players

11 Market Outlook

12 Appendix

Companies Mentioned

• Gilead
• Menarini Group
• Ono Pharmaceutical
• Les Laboratoires Servier
• Caladrius Biosciences
• Angionetics
• Milestone Pharmaceuticals
• Imbria Pharmaceuticals
• Astrazeneca
• Bristol-Myers Squibb
• NHS Greater Glasgow and Clyde

For more information about this report visit https://www.researchandmarkets.com/r/dglyw5

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.